Pfizer to price COVID treatment Paxlovid at $1,390 per course

  • 📰 Reuters
  • ⏱ Reading Time:
  • 43 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 21%
  • Publisher: 97%

Finance Finance Headlines News

Finance Finance Latest News,Finance Finance Headlines

Pfizer on Wednesday (PFE.N) said it will set the U.S. price for its COVID-19 antiviral treatment Paxlovid at nearly $1,400 per five-day course when it moves to commercial sales after government stocks run out.

Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease , is displayed in this picture illustration taken October 7, 2022. A morning and an evening does consists of one white 100-milligram tablet of Ritonavir and two pink 150-milligram tablets of PF-07321332. REUTERS/Wolfgang Rattay/Illustration/File Photosaid it will set the U.S.

The U.S. government paid around $530 per course for Paxlovid it has made available to Americans at no cost. The new list price before rebates and other discounts to insurers and pharmacy benefit managers is $1,390 per course, Pfizer said in an emailed statement. The United States purchased around 24 million courses of the oral two-drug treatment from Pfizer, and had still had a large supply, but arranged to return 7.9 million courses

Under that deal, a credit for the returned Paxlovid doses will pay for Pfizer to supply the pills at no charge to uninsured and underinsured Americans through 2028, and to patients insured under the government's Medicare and Medicaid programs through the end of next year.President Joe Biden's administration on Wednesday announced $3.5 billion in grants for projects to protect the aging U.S.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in FİNANCE

Finance Finance Latest News, Finance Finance Headlines